



# Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in HeLa cells



Subhajit Das<sup>a</sup>, Peter A. Edwards<sup>b</sup>, Julie C. Crockett<sup>a,\*</sup>, Michael J. Rogers<sup>c,d,1</sup>

<sup>a</sup> Musculoskeletal Research Programme, Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK

<sup>b</sup> School of Medicine, University of California, Los Angeles, CA 90095, USA

<sup>c</sup> Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia

<sup>d</sup> St. Vincent's Clinical School, University of New South Wales, Australia

## ARTICLE INFO

### Article history:

Received 16 October 2013

Received in revised form 12 December 2013

Accepted 17 December 2013

Available online 22 December 2013

### Keywords:

Bisphosphonate

Osteoporosis

Farnesyl diphosphate synthase

SREBP

Prenylation

Osteoclast

## ABSTRACT

Nitrogen-containing bisphosphonates (N-BPs) such as zoledronic acid (ZOL) are the gold standard treatment for diseases of excessive bone resorption. N-BPs inactivate osteoclasts via inhibition of farnesyl diphosphate synthase (FPPS), thereby preventing the prenylation of essential small GTPases. Not all patients respond to N-BP therapy to the same extent, and some patients, for example with tumour-associated bone disease or Paget's disease, appear to develop resistance to N-BPs. The extent to which upregulation of FPPS might contribute to these phenomena is not clear. Using quantitative PCR and western blot analysis we show that levels of FPPS mRNA and protein can be upregulated in HeLa cells by culturing in lipoprotein deficient serum (LDS) or by over-expression of SREBP-1a. Upregulated, endogenous FPPS was predominantly localised to the cytosol and did not co-localise with peroxisomal or mitochondrial markers. Upregulation of endogenous FPPS conferred resistance to the inhibitory effect of low concentrations of ZOL on the prenylation of the small GTPase Rap1a. These observations suggest that an increase in the expression of endogenous FPPS could confer at least partial resistance to the pharmacological effect of N-BP drugs such as ZOL in vivo.

© 2013 Elsevier B.V. All rights reserved.

## 1. Introduction

Over the last 4 decades, nitrogen-containing bisphosphonates (N-BPs) such as zoledronic acid (ZOL), have become the gold standard of treatment for post-menopausal osteoporosis as well as Paget's disease of bone (PDB) and tumour-associated bone diseases [1–4].

The molecular target of N-BPs is farnesyl diphosphate synthase (FPPS), a crucial enzyme at the branch point of cholesterol and isoprenoid synthesis in the mevalonate pathway [5]. Because they bind calcium ions, N-BPs accumulate quickly in the skeleton and are internalised by osteoclasts, leading to rapid inhibition of FPPS. The subsequent lack of intracellular isoprenoid lipids prevents the post-translational prenylation

of small GTPase signalling proteins such as Rap1a, leading to disruption of osteoclast function [5,6]. The accumulation of unprenylated Rap1a can therefore be used as a biochemical indicator of the pharmacological activity of N-BPs [7–11].

Resistance of patients to treatment with N-BPs has been recognized as a clinical issue in cancer-associated bone disease and PDB [1,12] where assessment of biochemical remission has been used as a measure of unresponsiveness [13]. This phenomenon is observed even in patients who have received intravenous BP therapy, thus ruling out lack of adherence to oral N-BP treatment. The molecular mechanism underlying this apparent drug resistance is unclear; upregulation of multidrug resistance protein 1, the antiapoptotic bcl-2 gene [14] and heat shock protein 27 [15] have been observed in tumour cell lines that have developed N-BP resistance, but these observations have yet to be shown to be clinically relevant. Given that FPPS is the major molecular target for N-BP drugs (reviewed in [5]), we explored the possibility, using a cellular model, that resistance to N-BPs could be acquired as a consequence of upregulation of this enzyme.

Although prolonged N-BP treatment can result in increased FPPS expression in cultured cells [16–18], a model system in which endogenous FPPS expression can be rapidly modulated, with the intention of altering responsiveness to N-BPs, has not been examined. Expression of endogenous FPPS, as well as other enzymes of the mevalonate pathway, is

Abbreviations: BMD, bone mineral density; FPPS, farnesyl diphosphate synthase; HMG CoA reductase, 3-hydroxy 3-methyl-glutaryl CoA reductase; LDS, lipoprotein deficient serum; N-BP, nitrogen-containing bisphosphonate; SREBP, sterol regulatory element binding protein; ZOL, zoledronic acid

\* Corresponding author at: Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB252ZD, UK. Tel.: +44 1224 437472.

E-mail address: [j.c.crockett@abdn.ac.uk](mailto:j.c.crockett@abdn.ac.uk) (J.C. Crockett).

<sup>1</sup> Contributed equally to the manuscript.

upregulated by sterol regulatory element binding proteins (SREBPs) under conditions of sterol depletion [19,20], for example by culturing cells in the presence of lipoprotein deficient serum (LDS) [20,21]. We therefore examined whether upregulation of endogenous FPPS, by culturing cells in LDS-containing medium, conferred resistance to the N-BP ZOL, measuring the accumulation of unprenylated Rap1a as a surrogate marker for inhibition of protein prenylation.

The exact subcellular location of endogenous FPPS is not clear, with evidence for both cytosolic and peroxisomal locations [22–25]. In 2007, an isoform of FPPS was identified that contains a mitochondrial targeting sequence, raising the possibility of a mitochondrial location for the enzyme [26]. We therefore examined the subcellular localisation of LDS-induced endogenous FPPS in peroxisomes, mitochondria or the cytosol. Since HeLa cells are reported to have intact peroxisomal import pathways [27], these cells are an ideal model with which to study the subcellular localisation of FPPS.

## 2. Materials and methods

### 2.1. Reagents

All reagents were purchased from Sigma Aldrich (Poole, UK), unless otherwise stated. Zoledronic acid (ZOL, hydrated disodium salt), provided by Novartis Pharma AG (Basel, Switzerland), was dissolved in PBS, adjusted to pH 7.4 and sterilized with 0.2 µm filter. Other reagents were MitoTracker-CMX-ROS 579–599 (Cat. No. M7512, Invitrogen), anti-myc antibody (9B11, mouse monoclonal antibody, Cat. No. 2276, Cell signalling), anti-PMP 70 antibody (Cat. No. ABT12, Millipore) and pDsRed2-Peroxi vector (Cat. No. 632418, Clontech). The 1470 bp cDNA encoding human SREBP-1a was cloned into the pcDNA3.1 vector to create the SREBP-1a-FLAG plasmid, kindly provided by Dr T. Osborne, University of California.

### 2.2. Cell culture

HeLa cells were maintained in DMEM (Life Technologies, Paisley, UK), containing 10% [v/v] foetal calf serum (FCS) and 1 mM glutamine. For each set of experiments, FPPS expression was manipulated by culturing cells in medium containing either 10% [v/v] foetal calf serum (FCS) or batch-matched lipoprotein-deficient foetal calf serum (LDS), or by transfecting the cells with FLAG-tagged SREBP-1a.

### 2.3. Quantitative RT-PCR

Cells were seeded into 6-well plates at a density of  $2 \times 10^5$  cells per well and incubated overnight. The cells were washed once with PBS, fresh medium with 10% [v/v] FCS or LDS was added and the plates were incubated for 24 h. The cells were then treated with 0–50 µM ZOL for a further 24 h. Total RNA was extracted using TRIzol®. cDNA was reverse transcribed using SuperScript™ II Reverse Transcriptase (18064-022, Invitrogen). In a 20 µL reaction volume, 2 µg of RNA, 2 µM of random primer and 200 U of SuperScript™ II reverse transcriptase were mixed and incubated at 70 °C for 10 min, 42 °C for 50 min and finally 95 °C for 5 min.

For quantitative real time PCR, 3 µL of cDNA was added to 10 µL of LightCycler® 480 Probe Master (Roche), 0.2 µL of TaqMan® probe (Probe no. 46, Universal Probe Library), 0.2 µL of forward and reverse primers (20 µM) each and 1 µL of human GAPDH probe dye VIC-MGB (Applied Biosystems, 4326317E). The human FPPS gene specific intron spanning primers between exons 2 and 3 were designed using Universal Probe library software and purchased from Sigma-GenoSys (forward primer: 5'-CAGCTTTCTACTCTCTACCTTCC-3', reverse primer: 5'-GCTCCTTCTCGCCATCAAT-3'). The results were analysed using LightCycler® 480 software 1.5 and FPPS was normalised to GAPDH and presented as a ratio ( $\text{Ratio} = E^{\text{target}\Delta\text{CT}(\text{treated-control})} / E^{\text{GAPDH}\Delta\text{CT}(\text{treated-control})}$ ).

### 2.4. Western blot analysis

Cells were seeded into 6-well plates at a density of  $2 \times 10^5$  cells per well and incubated overnight. The cells were washed once with PBS, fresh medium with 10% [v/v] FCS or LDS was added. The cells were incubated for 24 h then treated with 0–50 µM ZOL for a further 24 h and cell lysates were analysed by western blotting with antibodies specific for unprenylated Rap1a (goat polyclonal, Santa Cruz Biotechnology; SC-1482) and total Rap1 (rabbit monoclonal, Cell Signalling Technologies; 2399) as previously described [28], or for FPPS (1/1000 dilution of affinity-purified rabbit anti-serum), FLAG-SREBP1a using M2-antiFLAG antibody (1/1000 dilution; Sigma, Poole, UK) together with infrared-labelled secondary antibodies (LI-COR, Cambridge, UK). The blots were analysed on an infrared scanner (LI-COR, Cambridge, UK) with Odyssey software.

### 2.5. Immunofluorescence staining of FPPS

FPPS cDNA containing an apparent mitochondrial targeting sequence in exon 2 [26] (Ensembl, transcript: FDPS-001 (ENST00000356657)) was inserted into pcDNA™ 3.1/myc-His A vector (Invitrogen) using T4 DNA ligase. The ligated product was transformed into XL-1 Blue super-competent *Escherichia coli* and the plasmid was purified and sequence verified.

HeLa cells were seeded on coverslips into 48 well plates. After overnight incubation they were either treated with medium containing 10% [v/v] LDS or 10% [v/v] FCS. Some cultures were transfected with the FPPS-encoding plasmid using jetPRIME™ transfection reagent. To label peroxisomes, cells were also transfected with pDsRed2-Peroxi vector. Following transfections, cells were incubated for 24 h before transferring to LDS or FCS containing medium for a further 24 h. Mitochondria were labelled by incubating cells with 100 nM MitoTracker® Red CMXRos for 30 min at 37 °C at the end of the culture period. The cells were fixed in 4% [v/v] paraformaldehyde, washed and then permeabilised with 0.1% [v/v] Triton-X-100 for 20 min. The cells were incubated with 10% [v/v] normal goat serum in PBS for 30 min and then with affinity-purified rabbit polyclonal FPPS anti-serum ([29]; 1/1000 dilution) followed by goat anti-rabbit 488 antibody (1/150 dilution; Invitrogen). To confirm that the pDsRed2-Peroxi vector labelled peroxisomes, some cells were co-stained with anti-PMP70 antibody (1/1000 dilution). Cells were analysed and images captured on a Carl Zeiss LSM510 META Confocal microscope with Zen 2009 software.

### 2.6. Transfection with SREBP-1a plasmid

HeLa cells were seeded in 6 well plates at a density of  $2 \times 10^5$  cells per well and incubated overnight in DMEM containing 10% [v/v] FCS. Cells were then transfected with FLAG-tagged SREBP-1a (a generous gift from Dr Timothy Osborne, University of California) using jetPRIME™ transfection kit (114–15, Polyplus transfection™). The culture medium was replaced after 4 h and cells were incubated for 18 h. The medium was replaced with fresh medium containing 0–25 µM ZOL and cultures were incubated for a further 6 h with or without ZOL, after which the cells were lysed for western blot analysis.

### 2.7. Statistical analysis

Mean densitometric measurements from western blots of FCS- and LDS-treated cells were compared using an unpaired *t*-test (SPSS, version 20).

## 3. Results and discussion

The expression of FPPS is upregulated in the absence of sterols via binding of SREBP-1 protein to the FPPS promoter [30–32]. Consistent with this, in HeLa cells, as in other cell lines such as THP-1, HepG2 and

Download English Version:

<https://daneshyari.com/en/article/8302415>

Download Persian Version:

<https://daneshyari.com/article/8302415>

[Daneshyari.com](https://daneshyari.com)